ClinicalTrials.gg
RecruitingNCT07425067Updated Feb 20, 2026

Upper Gastrointestinal Endoscopy in HIV-infected Individuals

An observational study in HIV, sponsored by Centre Hospitalier Universitaire Saint Pierre. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Centre Hospitalier Universitaire Saint Pierre · Observational

From the registry’s dates

  • Started Jan 2004; still recruiting 22 years 10 months later.
Study type
Observational
Model
Case-only
Time perspective
Other
Enrollment
2,500
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The aim of this registry is to collect prospectively demographic characteristics and upper gastrointestinal endoscopy diagnoses over a long-term period, in people living with HIV, undergoing upper gastrointestinal endoscopy

02

Conditions studied

  • HIV
03

In context

Lead sponsor

Centre Hospitalier Universitaire Saint Pierre is the lead sponsor of 78 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Ppeople living with HIV, undergoing upper gastrointestinal endoscopy

Eligibility criteria

Inclusion criteria: adults aged 18 years or older; first upper gastrointestinal endoscopy; written .

Exclusion criteria: inability to provide informed consent or refusal.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Other
Enrollment
2,500 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Upper endoscopy in HIV infected patients

    Diagnostic Test: Gastroscopy

Interventions

  • Diagnostic testGastroscopy
06

What researchers measure

Primary outcomes

  1. Outcome: demographic, clinical characteristics; endoscopy findings; and pathology diagnoses

    Time frame: 2026

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07425067
Lead sponsor
Centre Hospitalier Universitaire Saint Pierre
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Jan 1, 2004
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Feb 20, 2026

Study contacts

Marcel Nkuize, PhD
Contact
marcel.nkuize@stpierre-bru.be
+32 25354658
Marcel Nkuize, PhD
study director · Centre Hospitalier Universitaire Saint Pierre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion